NEW YORK, July 05, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the American Depositary Shares of Sky Solar Holdings, Ltd. (NASDAQ:SKYS): (1) pursuant and/or traceable to Sky Solar’s initial public offering on or about November 18, 2014; and/or (2) on the open market from November 14, 2014 through June 12, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Sky Solar investors under the federal securities laws.
To join the Sky Solar class action, go to http://rosenlegal.com/cases-1145.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that defendants during the Class Period made false and misleading statements and/or failed to disclose that: (1) Sky Solar’s Code of Business Conduct and Ethics and its enforcement by the Board of Directors were inadequate to detect and/or deter misconduct by Sky Solar’s officers and directors; (2) consequently, Sky Solar’s founder Weili Su was involved in undisclosed misconduct during his tenure at Sky Solar; and (3) as a result, Sky Solar’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 15, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1145.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Britain Courts Anthropic Amid US Defense Department Dispute
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Apple Turns 50: From Garage Startup to AI Crossroads
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



